Sisram Medical H1 2026: Injectables Revenue Surges 54%, DAXXIFY Tops 30,000 Vials in China

The Quick Take

• Sisram Medical (SRAMF) H1 2026 injectables revenue surges 54%, offsetting weakness in other segments.
• DAXXIFY botulinum toxin shipments surpass 30,000 vials in China, marking a commercial milestone.
• International markets outside North America grow 16.7%, demonstrating geographic diversification progress.

Sisram Medical's first-half 2026 results demonstrate the commercial momentum behind its injectables portfolio, with revenue growing 54% — a rate that substantially outpaces the aesthetic medicine sector's average. The performance reflects pricing power in high-demand aesthetic procedures and the successful penetration of DAXXIFY, the botulinum toxin product, into the Chinese market where 30,000 vials have now been shipped to Chinese aesthetic practitioners.

The 16.7% growth in international markets outside North America signals that Sisram is executing a multi-region expansion strategy, reducing historical concentration risk. China's importance to the aesthetic medicine market cannot be overstated: consumer spending on medical aesthetics has been recovering strongly from COVID-era disruptions, and companies with regulatory approval and established distribution networks are positioned for outsized growth through the recovery cycle.

Margin pressure remains a flagged concern, suggesting the strong volume growth is coming at a cost in promotional spend, distribution investment, or product mix effects. Sisram's ability to manage margin dilution while maintaining injectable revenue momentum will be the critical operational balance in H2 2026, as scaling a medical aesthetics business in both Western and Asian markets simultaneously requires substantial commercial investment.

Synthesized from 1 source — full coverage, sentiment breakdown, and forward signals below.